Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the 340B Drug Pricing Program. The complaint claims Amgen bypassed federal ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

Health Affairs' Rob Lott interviews Sayeh Nikpay of the University of Minnesota about her recent paper exploring how The Medicaid Drug Rebate Program and the 340B Program interact in ways that can ...

On January 15, 2026, President Trump released a one-page health policy framework. Among other things, the document includes ...

Pharmacy benefit managers (PBMs) play a central but often invisible role in the prescription drug supply chain, influencing ...

The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of ...

The cost of prescription drugs is certain to be a hot-button issue in the coming Illinois legislative session with two separate measures making for curious bedfellows in Springfield.

Eli Lilly expand 340B reporting requirements to include all covered entities submitting claims-level data by Feb. 1, 2026, with some state exemptions.

From Medicaid shifts to prior auth reform and doula coverage, Missouri legislators weigh broad health care changes in the ...

Sagebrush Health Services has filed a lawsuit in California state court accusing Amgen of unlawfully cutting off 340B discounted drug sales to its Nevada clinics and reclaiming at least US$7,000,000 ...

Continued support of 340B is vital for diverse communities and small business owners in the state.

More than 57 million rural Americans depend on their hospital not only as an important source of care but also as a critical component of their area's economic and social framework. Rural hospitals ...